Copyright © 2005, European Society of Cardiology
Arg–Gly–Asp (RGD)-containing peptides increase soluble guanylate cyclase in contractile cells
aDepartment of Physiology, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
bNephrology Section, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
cResearch Unit, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
dDepartment of Medicine, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
* Corresponding author. Departamento de Fisiología, Facultad de Medicina, Universidad de Alcalá, Alcalá de Henares. 28871-Madrid, Spain. Tel.: +34 918854519; fax: +34 8854590. Email address: manuel.rodriguez{at}uah.es
Objectives: Alterations in NO/cGMP signaling have been associated with vascular dysfunction. Here, we tested whether peptides containing arginine–glycine–aspartic acid (RGD) motifs, commonly found on the binding sites of extracellular matrix to integrins, could increase the expression and function of soluble guanylate cyclase (sGC) in human mesangial cell (HMC), and human aortic smooth muscle (HASMC) cells.
Methods and results: Arginine–glycine–aspartic acid–serine (RGDS) promoted an up-regulation in the sGC β1 subunit steady-state level, both in HMC and HASMC, in a time- and dose-dependent manner. The cellular effects of RGDS-stimulation of sGC expression was an enhanced cellular response to sodium nitroprusside, resulting in elevated cGMP levels and vasodilator-stimulated phosphoprotein (VASP) phosphorylation in both kinds of cells, and an increased NO relaxing effect on cells precontracted with H2O2 or Angiotensin II. Moreover, RGDS was able to restore the sGC levels that had been previously decreased by long term exposure to NO donors. RGDS effects on sGC regulation were due to the specific interaction with 
5β1 integrin. To investigate the intracellular mechanisms activated after RGDS cell treatment, pharmacological kinase inhibitors were used. The effect of RGDS on sGC protein content was completely abolished by treating the cells with c-Jun N-terminal kinase (JNK) inhibitors. In addition, c-fos and c-jun were found in the cell nuclei after RGDS treatment, suggesting that the RGDS effect could be mediated by the AP-1 transcription factor.
Conclusion: Results provide evidence of a mechanism able to increase the sGC protein content linked to increased activity in contractile cells, not only in basal conditions, but also after the down-regulation of the receptor by its own substrate. Elucidation of this novel mechanism provides a rationale for future pharmacotherapy in certain vascular diseases.
KEYWORDS Soluble guanylate cyclase; Nitric oxide; Extracellular matrix; Hypertension; Smooth muscle; Vasoconstriction/dilation
Time for primary review 25 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. J. Pearce, J. M. Williams, C. R. White, and T. M. Lincoln Effects of chronic hypoxia on soluble guanylate cyclase activity in fetal and adult ovine cerebral arteries J Appl Physiol, July 1, 2009; 107(1): 192 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Ruiz-Torres, M. Griera, A. Chamorro, M. L. Diez-Marques, D. Rodriguez-Puyol, and M. Rodriguez-Puyol Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences Cardiovasc Res, April 1, 2009; 82(1): 125 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Packer Soluble guanylate cyclase (sGC) down-regulation by abnormal extracellular matrix proteins as a novel mechanism in vascular dysfunction: Implications in metabolic syndrome Cardiovasc Res, February 1, 2006; 69(2): 302 - 303. [Full Text] [PDF]
|
|